View Future GrowthThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsPCAS 과거 순이익 실적과거 기준 점검 2/6PCAS의 수입은 연평균 -40.1%의 비율로 감소해 온 반면, Life Sciences 산업은 수입이 연평균 4.9% 증가했습니다. 매출은 연평균 0.7%의 비율로 증가해 왔습니다. PCAS의 자기자본이익률은 122.1%이고 순이익률은 3.8%입니다.핵심 정보-40.14%순이익 성장률-40.15%주당순이익(EPS) 성장률Life Sciences 산업 성장률26.83%매출 성장률0.67%자기자본이익률122.06%순이익률3.81%최근 순이익 업데이트30 Jun 2023최근 과거 실적 업데이트분석 기사 • Sep 14Statutory Earnings May Not Be The Best Way To Understand PCAS' (EPA:PCA) True PositionPCAS SA's ( EPA:PCA ) stock rose after it released a robust earnings report. Despite the strong profit numbers, we...Reported Earnings • Apr 02Full year 2022 earnings releasedFull year 2022 results: Revenue: €226.4m (up 21% from FY 2021). Net loss: €48.8m (loss widened 21% from FY 2021).공시 • Feb 07PCAS SA to Report Fiscal Year 2022 Results on Mar 30, 2023PCAS SA announced that they will report fiscal year 2022 results on Mar 30, 2023Reported Earnings • Feb 28Full year 2021 earnings: Revenues miss analyst expectationsFull year 2021 results: Revenue: €187.0m (down 3.7% from FY 2020). Net loss: €40.5m (loss widened 171% from FY 2020). Revenue missed analyst estimates by 1.8%.Reported Earnings • Sep 12First half 2021 earnings released: €0.38 loss per share (vs €0.42 loss in 1H 2020)The company reported a solid first half result with reduced losses, improved revenues and improved control over expenses. First half 2021 results: Revenue: €106.3m (up 1.1% from 1H 2020). Net loss: €5.21m (loss narrowed 11% from 1H 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 57 percentage points per year, which is a significant difference in performance.Reported Earnings • Mar 02Full year 2020 earnings releasedThe company reported a poor full year result with increased losses, weaker revenues and weaker control over costs. Full year 2020 results: Revenue: €194.1m (down 3.4% from FY 2019). Net loss: €14.9m (loss widened 8.8% from FY 2019).모든 업데이트 보기Recent updates분석 기사 • Sep 14Statutory Earnings May Not Be The Best Way To Understand PCAS' (EPA:PCA) True PositionPCAS SA's ( EPA:PCA ) stock rose after it released a robust earnings report. Despite the strong profit numbers, we...New Risk • Aug 18New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: €88.6m (US$96.4m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€53m free cash flow). Negative equity (-€18m). Earnings have declined by 63% per year over the past 5 years. Minor Risk Market cap is less than US$100m (€88.6m market cap, or US$96.4m).공시 • Jun 02DIC Corporation (TSE:4631) completed the acquisition of PCAS Canada Inc. from PCAS SA (ENXTPA:PCA).DIC Corporation (TSE:4631) agreed to acquire PCAS Canada Inc. from PCAS SA (ENXTPA:PCA) for an enterprise value of €88.2 million on May 25, 2023. The sale is not subject to any condition precedents. Therefore, the execution of the related agreements by PCAS and DIC Corporation as well as the closing of the transaction will be completed within the coming days. DIC Corporation (TSE:4631) completed the acquisition of PCAS Canada Inc. from PCAS SA (ENXTPA:PCA) on June 1, 2023. On completion, PCAS Canada Inc was renamed “Innovation DIC Chimitroniques Inc.” (English company name: “Innovation DIC Chemitronics Inc.”).공시 • May 09PCAS in Talks to Sell Canada Unit to DICPCAS SA (ENXTPA:PCA) announced it has entered into exclusive talks to sell its Canadian subsidiary to DIC Corporation (TSE:4631). The proposed deal gives PCAS Canada Inc. an enterprise value of EUR 88.2 million (USD 97.1 million). A potential transaction hinges on an obligatory information-consultation process of the competent workers’ councils, after authorisation of PCAS’ supervisory board and its majority shareholder, Seqens, a press release said.Reported Earnings • Apr 02Full year 2022 earnings releasedFull year 2022 results: Revenue: €226.4m (up 21% from FY 2021). Net loss: €48.8m (loss widened 21% from FY 2021).공시 • Feb 07PCAS SA to Report Fiscal Year 2022 Results on Mar 30, 2023PCAS SA announced that they will report fiscal year 2022 results on Mar 30, 2023Board Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 1 highly experienced director. 1 independent director (3 non-independent directors). Independent Director Jacqueline Lecourtier was the last independent director to join the board, commencing their role in 2014. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Board Change • Apr 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 1 highly experienced director. No independent directors (4 non-independent directors). Chairman of the Board Pierre Luzeau was the last director to join the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Reported Earnings • Feb 28Full year 2021 earnings: Revenues miss analyst expectationsFull year 2021 results: Revenue: €187.0m (down 3.7% from FY 2020). Net loss: €40.5m (loss widened 171% from FY 2020). Revenue missed analyst estimates by 1.8%.분석 기사 • Dec 19Is PCAS (EPA:PCA) A Risky Investment?Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Reported Earnings • Sep 12First half 2021 earnings released: €0.38 loss per share (vs €0.42 loss in 1H 2020)The company reported a solid first half result with reduced losses, improved revenues and improved control over expenses. First half 2021 results: Revenue: €106.3m (up 1.1% from 1H 2020). Net loss: €5.21m (loss narrowed 11% from 1H 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 57 percentage points per year, which is a significant difference in performance.분석 기사 • May 24Is PCAS (EPA:PCA) Weighed On By Its Debt Load?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...분석 기사 • Mar 02Did You Miss PCAS' (EPA:PCA) 48% Share Price Gain?These days it's easy to simply buy an index fund, and your returns should (roughly) match the market. But the truth is...Reported Earnings • Mar 02Full year 2020 earnings releasedThe company reported a poor full year result with increased losses, weaker revenues and weaker control over costs. Full year 2020 results: Revenue: €194.1m (down 3.4% from FY 2019). Net loss: €14.9m (loss widened 8.8% from FY 2019).공시 • Feb 26PCAS SA, Annual General Meeting, May 12, 2021PCAS SA, Annual General Meeting, May 12, 2021, at 10:00 Central European Standard Time.Is New 90 Day High Low • Feb 06New 90-day high: €11.50The company is up 16% from its price of €9.95 on 05 November 2020. The French market is up 14% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Life Sciences industry, which is up 3.0% over the same period.공시 • Jan 29PCAS SA to Report Fiscal Year 2020 Results on Feb 25, 2021PCAS SA announced that they will report fiscal year 2020 results on Feb 25, 2021Is New 90 Day High Low • Jan 20New 90-day high: €10.70The company is up 3.0% from its price of €10.40 on 22 October 2020. The French market is up 14% over the last 90 days, indicating the company underperformed over that time. However, its price trend is similar to the Life Sciences industry, which is also up 3.0% over the same period.분석 기사 • Nov 25PCAS'(EPA:PCA) Share Price Is Down 48% Over The Past Three Years.In order to justify the effort of selecting individual stocks, it's worth striving to beat the returns from a market...Is New 90 Day High Low • Nov 11New 90-day low: €9.25The company is down 16% from its price of €11.00 on 12 August 2020. The French market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is up 11% over the same period.매출 및 비용 세부 내역PCAS가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이ENXTPA:PCA 매출, 비용 및 순이익 (EUR Millions)날짜매출순이익일반관리비연구개발비30 Jun 232309149031 Mar 23228-20149031 Dec 22226-49149030 Sep 22208-58146030 Jun 22191-67143031 Mar 22189-54140031 Dec 21187-40137030 Sep 21191-27135030 Jun 21195-14133031 Mar 21195-15132031 Dec 20194-15132030 Sep 20199-13131030 Jun 20204-11130031 Mar 20202-12127031 Dec 19201-14123030 Sep 19205-9181030 Jun 19209-6120031 Mar 19208-3119031 Dec 182070119030 Sep 18208-159030 Jun 182080117031 Mar 182133115031 Dec 172186114030 Sep 172106110030 Jun 172026107031 Mar 171976105031 Dec 161927103030 Sep 161917101030 Jun 16189898031 Mar 16184895031 Dec 15179992030 Sep 15175789030 Jun 15172587031 Mar 15169486031 Dec 14166384030 Sep 14164284030 Jun 14161283031 Mar 14163384031 Dec 13165384030 Jun 13171684031 Mar 13171684031 Dec 121716850양질의 수익: PCA의 비현금 수익 수준이 높습니다.이익 마진 증가: PCA는 과거에 흑자전환했습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: PCA는 지난 5년 동안 흑자전환하며 연평균 -40.1%의 수익 성장을 기록했습니다.성장 가속화: PCA는 지난해 흑자전환하여 5년 평균과 수익 성장률을 비교하기 어렵습니다.수익 대 산업: PCA는 지난해 흑자전환하여 지난 해 수익 성장률을 Life Sciences 업계(5.4%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: PCA의 자본 수익률(122.06%)은 뛰어남이지만 높은 부채 수준으로 인해 왜곡되어 있습니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YPharmaceuticals-biotech 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2023/12/11 09:47종가2023/12/08 00:00수익2023/06/30연간 수익2022/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스PCAS SA는 3명의 분석가가 다루고 있습니다. 이 중 명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Harold De DeckerODDO BHF Corporate & MarketsGeoffroy MichaletPortzamparc BNP ParibasPierre VauriceTPICAP Midcap
분석 기사 • Sep 14Statutory Earnings May Not Be The Best Way To Understand PCAS' (EPA:PCA) True PositionPCAS SA's ( EPA:PCA ) stock rose after it released a robust earnings report. Despite the strong profit numbers, we...
Reported Earnings • Apr 02Full year 2022 earnings releasedFull year 2022 results: Revenue: €226.4m (up 21% from FY 2021). Net loss: €48.8m (loss widened 21% from FY 2021).
공시 • Feb 07PCAS SA to Report Fiscal Year 2022 Results on Mar 30, 2023PCAS SA announced that they will report fiscal year 2022 results on Mar 30, 2023
Reported Earnings • Feb 28Full year 2021 earnings: Revenues miss analyst expectationsFull year 2021 results: Revenue: €187.0m (down 3.7% from FY 2020). Net loss: €40.5m (loss widened 171% from FY 2020). Revenue missed analyst estimates by 1.8%.
Reported Earnings • Sep 12First half 2021 earnings released: €0.38 loss per share (vs €0.42 loss in 1H 2020)The company reported a solid first half result with reduced losses, improved revenues and improved control over expenses. First half 2021 results: Revenue: €106.3m (up 1.1% from 1H 2020). Net loss: €5.21m (loss narrowed 11% from 1H 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 57 percentage points per year, which is a significant difference in performance.
Reported Earnings • Mar 02Full year 2020 earnings releasedThe company reported a poor full year result with increased losses, weaker revenues and weaker control over costs. Full year 2020 results: Revenue: €194.1m (down 3.4% from FY 2019). Net loss: €14.9m (loss widened 8.8% from FY 2019).
분석 기사 • Sep 14Statutory Earnings May Not Be The Best Way To Understand PCAS' (EPA:PCA) True PositionPCAS SA's ( EPA:PCA ) stock rose after it released a robust earnings report. Despite the strong profit numbers, we...
New Risk • Aug 18New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: €88.6m (US$96.4m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€53m free cash flow). Negative equity (-€18m). Earnings have declined by 63% per year over the past 5 years. Minor Risk Market cap is less than US$100m (€88.6m market cap, or US$96.4m).
공시 • Jun 02DIC Corporation (TSE:4631) completed the acquisition of PCAS Canada Inc. from PCAS SA (ENXTPA:PCA).DIC Corporation (TSE:4631) agreed to acquire PCAS Canada Inc. from PCAS SA (ENXTPA:PCA) for an enterprise value of €88.2 million on May 25, 2023. The sale is not subject to any condition precedents. Therefore, the execution of the related agreements by PCAS and DIC Corporation as well as the closing of the transaction will be completed within the coming days. DIC Corporation (TSE:4631) completed the acquisition of PCAS Canada Inc. from PCAS SA (ENXTPA:PCA) on June 1, 2023. On completion, PCAS Canada Inc was renamed “Innovation DIC Chimitroniques Inc.” (English company name: “Innovation DIC Chemitronics Inc.”).
공시 • May 09PCAS in Talks to Sell Canada Unit to DICPCAS SA (ENXTPA:PCA) announced it has entered into exclusive talks to sell its Canadian subsidiary to DIC Corporation (TSE:4631). The proposed deal gives PCAS Canada Inc. an enterprise value of EUR 88.2 million (USD 97.1 million). A potential transaction hinges on an obligatory information-consultation process of the competent workers’ councils, after authorisation of PCAS’ supervisory board and its majority shareholder, Seqens, a press release said.
Reported Earnings • Apr 02Full year 2022 earnings releasedFull year 2022 results: Revenue: €226.4m (up 21% from FY 2021). Net loss: €48.8m (loss widened 21% from FY 2021).
공시 • Feb 07PCAS SA to Report Fiscal Year 2022 Results on Mar 30, 2023PCAS SA announced that they will report fiscal year 2022 results on Mar 30, 2023
Board Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 1 highly experienced director. 1 independent director (3 non-independent directors). Independent Director Jacqueline Lecourtier was the last independent director to join the board, commencing their role in 2014. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Board Change • Apr 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 1 highly experienced director. No independent directors (4 non-independent directors). Chairman of the Board Pierre Luzeau was the last director to join the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Reported Earnings • Feb 28Full year 2021 earnings: Revenues miss analyst expectationsFull year 2021 results: Revenue: €187.0m (down 3.7% from FY 2020). Net loss: €40.5m (loss widened 171% from FY 2020). Revenue missed analyst estimates by 1.8%.
분석 기사 • Dec 19Is PCAS (EPA:PCA) A Risky Investment?Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Reported Earnings • Sep 12First half 2021 earnings released: €0.38 loss per share (vs €0.42 loss in 1H 2020)The company reported a solid first half result with reduced losses, improved revenues and improved control over expenses. First half 2021 results: Revenue: €106.3m (up 1.1% from 1H 2020). Net loss: €5.21m (loss narrowed 11% from 1H 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 57 percentage points per year, which is a significant difference in performance.
분석 기사 • May 24Is PCAS (EPA:PCA) Weighed On By Its Debt Load?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...
분석 기사 • Mar 02Did You Miss PCAS' (EPA:PCA) 48% Share Price Gain?These days it's easy to simply buy an index fund, and your returns should (roughly) match the market. But the truth is...
Reported Earnings • Mar 02Full year 2020 earnings releasedThe company reported a poor full year result with increased losses, weaker revenues and weaker control over costs. Full year 2020 results: Revenue: €194.1m (down 3.4% from FY 2019). Net loss: €14.9m (loss widened 8.8% from FY 2019).
공시 • Feb 26PCAS SA, Annual General Meeting, May 12, 2021PCAS SA, Annual General Meeting, May 12, 2021, at 10:00 Central European Standard Time.
Is New 90 Day High Low • Feb 06New 90-day high: €11.50The company is up 16% from its price of €9.95 on 05 November 2020. The French market is up 14% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Life Sciences industry, which is up 3.0% over the same period.
공시 • Jan 29PCAS SA to Report Fiscal Year 2020 Results on Feb 25, 2021PCAS SA announced that they will report fiscal year 2020 results on Feb 25, 2021
Is New 90 Day High Low • Jan 20New 90-day high: €10.70The company is up 3.0% from its price of €10.40 on 22 October 2020. The French market is up 14% over the last 90 days, indicating the company underperformed over that time. However, its price trend is similar to the Life Sciences industry, which is also up 3.0% over the same period.
분석 기사 • Nov 25PCAS'(EPA:PCA) Share Price Is Down 48% Over The Past Three Years.In order to justify the effort of selecting individual stocks, it's worth striving to beat the returns from a market...
Is New 90 Day High Low • Nov 11New 90-day low: €9.25The company is down 16% from its price of €11.00 on 12 August 2020. The French market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is up 11% over the same period.